The RESPECT-PAD Trial

NCT ID: NCT03298230

Last Updated: 2018-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-30

Study Completion Date

2019-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Peripheral arterial disease affects around 25% of the UK population aged over 55. Left untreated it can lead to debilitating pain, gangrene, amputation and death. It most commonly affects the lower limbs and in the earlier stages of the disease patients can present with a symptom known as intermittent claudication; pain felt in the legs which stops the patient from walking past a certain distance. Current National Institute for Healthcare and Excellence (NICE) guidelines recommend Supervised Exercise as first line treatment for patients with peripheral arterial disease presenting with intermittent claudication. Supervised exercise employs behaviour changing techniques which enable the patient to modify their lifestyles, improving their claudication symptoms, quality of life and reducing their cardiovascular risk. Despite this treatment being significantly more cost-effective than often employed complex endovascular management, most institutions don't offer such programmes citing lack of resources and compliance from clinicians and patients alike.

The investigators propose a more cost-effective, resource-savvy solution in the form of REmotely SuPervised ExerCise Training (RESPECT). This allows the patient to exercise in the convenience of their own home, at a time of their choosing but still be supervised via fitness tracker technology and an online fitness platform. This randomised controlled trial will attempt to prove its' effectiveness in increasing claudication distance, improving functional ability, decreasing cardiovascular risk and improving quality of life whilst being more cost-effective than the currently recognised national first line treatment. This trial has the potential to revolutionise the management of patients with peripheral arterial disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Arterial Disease Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

REmotely SuPervised Exercise Training

12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.

Group Type EXPERIMENTAL

REmotely SuPervised Exercise Training

Intervention Type BEHAVIORAL

As described in the Arms section.

Supervised Exercise Training

As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.

Group Type ACTIVE_COMPARATOR

Supervised Exercise Training

Intervention Type BEHAVIORAL

As described in the Arms section.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

REmotely SuPervised Exercise Training

As described in the Arms section.

Intervention Type BEHAVIORAL

Supervised Exercise Training

As described in the Arms section.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients willing and able to undertake supervised or home-based exercise training aged between 40 and 85
2. Positive Edinburgh questionnaire for intermittent claudication (APPENDIX H)
3. Proven peripheral arterial disease on diagnostic imaging
4. Ankle Brachial Pressure Index (ABPI) \<0.9
5. Fontaine Classification (APPENDIX I) of PAD Stage II
6. Conservative management plan agreed for by Consultant Vascular Surgeon.

Exclusion Criteria

1. Critical limb ischaemia
2. Asymptomatic peripheral arterial disease
3. Ambulation limited by co-morbid condition other than claudication:

Severe coronary artery disease, angina pectoris, chronic lung disease, neurological disorder, arthritis, amputation
4. Contraindication to exercise training (AHA guidelines):71 acute MI (within 1 week), unstable angina, uncontrolled cardiac arrhythmias causing symptoms or haemodynamic compromise, active endocarditis, symptomatic severe aortic stenosis, acute pulmonary embolus, acute noncardiac disorder than may be aggravated by exercise such as infection, thyrotoxicosis, acute myocarditis, known physical disability that would preclude safe and adequate testing, known thrombosis of the lower limb, known left main stem coronary stenosis, moderate stenotic valvular heart disease, pulmonary hypertension, hypertrophic cardiomyopathy, atrio-ventricular block.
5. Psychiatric disorder precluding them from consenting for research and/or exercise training
6. Arterial reconstruction in the previous 12 months or planned within the next 6 months.
7. Recent or upcoming major surgery (within 3 months)
8. Unwilling or unable to attend/perform exercise training
9. Non-atherosclerotic cause of PAD
10. Other significant medical problems which impact on the patient's ability to complete a 12-week exercise programme, which could include:

malignancy, chronic renal disease, chronic liver disease or anaemia, active substance abuse, dementia
Minimum Eligible Age

30 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Manchester

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Charles McCollum

Professor of Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Adam Haque

Role: CONTACT

01612915848

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

224506

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PAD Screening Study
NCT05584072 UNKNOWN